| Document |
Document Title |
|
WO/2024/081428A2 |
Biologically active AhR ligand compounds, and pharmaceutical combinations comprising such compounds, tor treating proliferative cell diseases, such as cancer. Therapeutic combinations also are disclosed that comprise at least one AhR lig...
|
|
WO/2024/081688A2 |
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
|
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
|
WO/2024/077224A2 |
The present invention relates to compositions and methods for preventing or treating diseases or disorders involving nucleic acid damage, such as cancer, in a subject, as well as methods of identifying gut microbes, strains or metabolite...
|
|
WO/2024/077155A1 |
The present invention provides a method of delivering a tumor-targeting bacterium to a tumor site in an individual having cancer, comprising orally administering to the individual an effective amount of the tumor-targeting bacterium or b...
|
|
WO/2024/077297A2 |
Provided are methods of administering a peptide antagonist of CCAAT/enhancer-binding protein beta (C/EBPβ) in combination with an immunomodulating agent.
|
|
WO/2024/075089A1 |
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will a...
|
|
WO/2024/076245A1 |
The invention provides a method of enhanced ultrasound ablation and a composition for the use thereof. The method comprises: creating at least one ablation-assisting bubble proximate to a target region by: administering a cluster composi...
|
|
WO/2024/077106A2 |
Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.
|
|
WO/2024/077042A2 |
A method for treating a neutrophilic lung disease in a human subject in need thereof is disclosed, including administering a pharmaceutical composition including an effective amount of an IL-IRa (e.g., rhIL-1Ra) to the human subject, whe...
|
|
WO/2024/077130A1 |
The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (I...
|
|
WO/2024/077286A2 |
Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK...
|
|
WO/2024/077264A2 |
The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., ...
|
|
WO/2024/068100A1 |
Metal based nanoparticles coated with a polymer functionalized with thiol groups and 5 -NH groups, said polymer preferably being selected among thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic ac...
|
|
WO/2024/071530A1 |
The present invention relates to fluorescent nanodiamond coated with porous polydopamine, a method for preparing the fluorescent nanodiamond, and novel use of the fluorescent nanodiamond. The fluorescent nanodiamond coated with porous po...
|
|
WO/2024/064766A2 |
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial usin...
|
|
WO/2024/064807A2 |
Methods of treatment of medulloblastoma by administering thyroid hormone (T3) to a subject are provided herein.
|
|
WO/2024/064898A2 |
Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
|
|
WO/2024/064879A2 |
Provided herein are methods for treating inflammatory diseases, such as inflammatory bowel disease (IBD), by administering to a subject an agent to inhibit interferon lambda (IFNL) signaling in intestinal epithelial cells. Such methods m...
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/064255A2 |
Disclosed are methods for identifying and treating a subject having obstructive sleep apnea.
|
|
WO/2024/064964A2 |
Described herein are methods of inducing proliferation of PRX1 expressing stem cells stem cells in a subject in need thereof, the method can include administering an effective amount of niclosamide, or a pharmaceutically acceptable salt,...
|
|
WO/2024/064749A2 |
A composition, method of making, and method of using an active agent against a myriad of known as well as unknown pathogens comprising: binding a live influenza virus with a neuraminidase inhibitor in vitro; and administering the active ...
|
|
WO/2024/059820A2 |
The present disclosure provides methods for restoring regulatory T cell (Treg) function. Methods of treating a disease (e.g., an autoimmune disease or a cancer) in a subject in need thereof are also disclosed. The present disclosure furt...
|
|
WO/2024/059654A2 |
This disclosure relates to compositions and methods for treating type 1 diabetes.
|
|
WO/2024/059834A2 |
Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T ce...
|
|
WO/2024/057156A1 |
A composition for making a model for simulating soft tissue using ICG ( indiocyanine green) type fluorescence, comprising a material in particle form suitable for emitting a fluorescence in the near infrared and comprising calcium oxide ...
|
|
WO/2024/059688A2 |
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling bet...
|
|
WO/2024/059549A2 |
A novel 3-marker microbial-related metabolite panel (3MMP), consisting of or comprising TMAO, indoleacrylic acid, and an indole derivative, and a novel 5-marker non-microbial metabolite panel, consisting of or comprising cholesterol gluc...
|
|
WO/2024/059757A2 |
Disclosed are methods and compositions related to reviving the functionality for exhausted T cells and methods of improving immunotherapy by inhibiting T cell exhaustion. In one aspect, the methods and compositions described herein compr...
|
|
WO/2024/059480A2 |
The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to...
|
|
WO/2024/059878A2 |
A method to treat cancer using compounds that perform combinatorial targeting of the telomerase and the RNA-dependent RNA polymerase activity of TERT.
|
|
WO/2024/058504A1 |
The present invention, which is for the induction of at least one immune stimulation, relates to a method for treating primary cancer, cancer of scattered cells in the human body, and metastases thereof and, particularly, for inducing an...
|
|
WO/2024/059471A2 |
Described herein is the development of ureas and thioureas as small molecular weight fortilin inhibitors. Small molecular weight compounds that inhibit fortilin, as well as compositions, and methods for using same, described herein ameli...
|
|
WO/2024/053974A1 |
The present invention provides a contrast agent for optical imaging or a composition for photothermal therapy, each containing liposomes with a complex of indocyanine green and cyclodextrin, and a preparing method therefor. The compositi...
|
|
WO/2024/054934A1 |
The present application provides methods of treating a cancer in an individual that involves administering to the individual a SHP-1 inhibitor (such as TPI-1 or an analog or a derivative thereof) and a pro-inflammatory agent (such as a T...
|
|
WO/2024/054558A2 |
Compositions and methods for the treatment of CLEC 16 A- associated phenotypes and disorders are disclosed.
|
|
WO/2024/050109A2 |
Methods, compositions, and devices are provided for use in controlling jet lag, chronotype, and/or circadian rhythm in a patient. Patients can be treated with a vasopressin 1A receptor antagonist or a melanopsin agonist to control the pa...
|
|
WO/2024/050296A2 |
The present disclosure is directed to methods of inhibiting clonal hematopoiesis in a subject by administering a senolytic agent.
|
|
WO/2024/045275A1 |
Provided are an ultrasonic response type liposome nanoparticle, a preparation method therefor, and use thereof. The liposome nanoparticle comprises dimyristoylphosphatidylcholine, 1,2-dioleoyl-3-trimethyl ammonium-propane, distearoyl pho...
|
|
WO/2024/049933A2 |
Disclosed herein are compositions and methods relating to the inhibitors of the translesion synthesis (TLS) pathway, including methods of preventing or treating RNA viruses and prolonged symptoms (for example, long COVID).
|
|
WO/2024/050426A2 |
The present invention provides methods and compositions for treating cancers, as well as methods for increasing an immune response against a tumor, in a subject in need thereof by decreasing the expression and/or activity of Stub1 in an ...
|
|
WO/2024/050075A2 |
This invention provides novel phase-shift microbubbles (PSMBs) and methods of preparation and delivery thereof that are useful in treatment of vascular obstructions (e.g., deep vein thrombosis, pulmonary embolism, microvascular obstructi...
|
|
WO/2024/050537A2 |
A method of treating cancer in a subject using a kinome and/or phosphorylome analysis approach, a SPHINKS computational analysis, or a combination thereof to target master kinases driving the cancer state.
|
|
WO/2024/042018A1 |
The present invention relates to a topical composition comprising a) chlorine e6, or a topically acceptable salt thereof; or a topically acceptable liposome containing it; b) zinc salt of L-pyroglutamine acid; and c) optionally, one or m...
|
|
WO/2024/040728A1 |
Provided are a platinum-based drug carbon nanodot and a method for preparing same and a carbon nanodot protein compound and use thereof. The platinum-based drug carbon nanodot comprises a carbon-based core having the characteristic of vi...
|
|
WO/2024/041984A1 |
A composite resin particle comprising a dye and a resin selected from the group consisting of poly(amino acids), polyphosphazenes, polysaccharide derivatives, poly(esters), poly(ortho esters), poly(cyano-acrylates) and copolymers thereof...
|
|
WO/2024/044642A2 |
Compositions and methods for treating a cardiomyopathy, such as dilated cardiomyopathy (DCM) are provided. Embodiments of the present disclosure provide compositions having a bisphosphonate compound, wherein the compound acts as a struct...
|
|
WO/2024/044787A2 |
Certain intestinal or commensal bacteria (produced naturally or in vitro) induce Th17 cells, leading to production of IL-17, reducing lipid absorption, and thereby counteracting metabolic syndrome, obesity, and associated morbidities, su...
|
|
WO/2024/044774A2 |
Provided herein is a neoadjuvant therapy and/or adjuvant therapy for the treatment of uveal melanoma, inter alia, ocular tumors in uveal melanoma to reduce the incidence of metastasis and/or enucleation and/or preserving eye function.
|
